A Phase II Study of HY209 Gel for Atopic Dermatitis Patients (Shaperon)

NCT04530643 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: HY209 0.3%
DRUG: HY209 0.5%
DRUG: Placebo

Sponsor

Shaperon